,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu', '$azn', '$dsnky']
enhertu nearly halves risk of disease progression in her2-low breast cancer study $azn $dsnky #asco22 
#IME #CME #healthcare #innovation #DotConnector https://t.co/Ag09XUbNP3